With multidrug-resistant forms of tuberculosis on the rise, and the variable efficacy of the generic BCG vaccine, it is getting harder and harder to treat the disease. The Infectious Disease Research Institute (IDRI) is stepping up to the plate and taking its TB candidate to Phase IIa trials in South Africa.
India's IP policies suit South Africa just fine, official says, wants New Delhi to hold the line
South African health minister Aaron Motsoaledi wants India to hang tough on intellectual property (IP) challenges for pharmaceuticals because the country's role as a major supplier of affordable medicines needs to be lauded, not scolded.
South African regulator eases API oversight rules in face of shortages
South Africa, facing a growing number of drug shortages, particularly of penicillin, is changing its inspection requirements in a move that will make it easier for drugmakers to switch suppliers of active pharmaceutical ingredients (APIs).
After nixing CFR deal, Adcock stakeholders force chairman's resignation
Adcock Ingram chairman Khotso Mokhele last year rebuffed a Bidvest takeover offer, labeling it "opportunistic." Now, after teaming up to block Adcock's deal with Chile's CFR Pharmaceuticals, the two companies have forced his resignation.
Growing Novotech makes its way into Africa
Australian CRO Novotech is heading west with its global expansion effort, opening up shop in South Africa to broaden its access to diverse patient populations.
Novo Nordisk quits South African pharma group over 'satanic' PR campaign
First, South Africa proposed patent-law changes that would help foster generic drugs. Then, Big Pharma and its smaller colleagues in the country's pharma association hatched a counter-offensive: a $600,000 lobbying campaign against the measure. Now, Novo Nordisk has quit that group, the Innovative Pharmaceutical Association of South Africa (Ipasa), in protest.
Big Pharma accused of hatching 'satanic plot' in South Africa
South Africa's Minister of Health, Aaron Motsoaledi, lashed out on Friday at a report that Big Pharma is funding a PR campaign aimed at opposing new patent provisions favoring generic drugs, calling it "a conspiracy of satanic magnitude" that would lead to "genocide."
Key Adcock investor rebuffs CFR Pharma's new $1.2B offer
There's nothing like cold, hard cash in your pocket, and that fact may be enough to derail CFR Pharmaceuticals' takeover bid for South Africa's Adcock Ingram. Adcock's top shareholder has rejected a sweetened cash-and-stock offer from CFR, opening a window for rival bidder Bidvest Group to push its counteroffer through.
CFR chief angles for meeting with Adcock after top investor nixes $1.3B deal
Chile's CFR Pharmaceuticals is threatening to pull its $1.3 billion bid for South African drugmaker Adcock Ingram if the latter's biggest shareholder doesn't come on board with the deal. But CFR chief Alejandro Weinstein is in Johannesburg this week hoping to salvage the deal.
Top Adcock shareholder nixes CFR offer, endangering $1.3B deal
Chile-based CFR Pharmaceuticals has hit a wall in its quest to buy the South African drugmaker Adcock Ingram. Though leading Adcock shareholders had backed the $1.3 billion deal, the company's largest investor said no go.